CARAT

Chimeric Antigen Receptors (CARs) for Advanced Therapies


Description

CARAT will develop an innovative manufacturing platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR T cells including novel tracking tools. CARs (Chimeric Antigen Receptors) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T cells specifically towards killing of cancer cells. CARAT will establish complementary enabling technologies to obtain more effective and safer cellular products, improved gene delivery, better CARs design and innovative monitoring. Thereby, CARAT will deliver proof-of-principle for an innovative integrated solution to generate genetically modified ATMPs (advanced therapeutic medicinal products) that are specifically tailored towards cancer killing and thus serve patients with so far incurable solid tumours and hematologic malignancies.

Coordinator
Dr. Andrew Kaiser
Miltenyi Biotec GmbH
Phone: +49 2204 8306 2201
Email
Programme
Horizon 2020 & sub-programmes
Duration
48 months (January 2016 - December 2019)
Project funding
€ 5,989,158.75
Project partners
8
Technology readiness level
4-7
About Eurice

Eurice offers knowledge-based consultancy services in project and innovation management.

Eurice Head Office
Heinrich-Hertz-Allee 1
66386 St. Ingbert
Germany
Phone: +49 6894 388130
Email
Eurice Berlin
Alt-Reinickendorf 25
13407 Berlin
Germany
Phone: +49 30 374415840
Email